UK finalizes major veterinary reforms aimed at pet care costs

The UK has moved from investigation to action in one of the most consequential veterinary market interventions in recent years. On March 24, 2026, the Competition and Markets Authority published its final decision on veterinary services for household pets, concluding that competition concerns were harming pet parents and approving a broad remedies package aimed at price transparency, consumer choice, and stronger accountability across the sector. (gov.uk)

This moment has been building since the CMA launched its review in September 2023, gathered roughly 56,000 responses, and then escalated to a formal market investigation in May 2024. The inquiry focused on concerns including limited pricing visibility, weak disclosure of corporate ownership, barriers to shopping for medicines online, complaints handling gaps, and an outdated legal framework that regulates individual veterinarians but not veterinary businesses themselves. The CMA’s provisional decision arrived in October 2025, and the final report followed on March 24, 2026. (gov.uk)

The final remedies are concrete. Practices will need to post comprehensive price lists for standard services, diagnostics, written prescriptions, and cremation options; disclose common ownership on-site and online; and give written estimates in advance for treatment expected to cost £500 or more, except in emergencies. The CMA also capped written prescription fees at £21 for the first medicine and £12.50 for additional medicines, required practices to tell pet parents they can request a written prescription for online purchasing, and mandated a transparent in-house complaints process with mediation when disputes can’t be resolved. Out-of-hours providers will also be barred from imposing unreasonably long notice periods that make it hard for practices to switch. (gov.uk)

The reform package goes beyond consumer-facing disclosures. The CMA explicitly endorsed government plans for a new veterinary legislative framework, saying the current roughly 60-year-old regime is outdated and leaves business-level conduct insufficiently regulated. Under the CMA’s model, the RCVS would play a central role in monitoring compliance, operating comparison infrastructure, and supporting the remedies, funded by a levy on veterinary businesses. The CMA said its current estimate is £150 to £250 per practice for initial setup and £450 to £550 annually for ongoing RCVS costs. (gov.uk)

Reaction across the profession has been broadly supportive, but cautious. The RCVS said it supports many of the measures, especially around transparency, pricing, and mandatory business regulation, while raising concerns that some requirements could be complex, costly, or poorly targeted. It also stressed the need to preserve veterinary surgeons’ clinical autonomy regardless of business structure or commercial pressure. PDSA, meanwhile, welcomed the final report and said it was pleased charities providing small animal veterinary services were exempted from the CMA requirements after warning that some proposals could have diverted limited charitable resources. VetSurgeon’s roundup of industry reaction reported similar support from BVA, BVNA, and BSAVA, alongside warnings from SPVS about operational and commercial consequences for practices. (rcvs.org.uk)

Why it matters: For veterinary professionals, the UK case is an important test of how far competition regulators may go when concerns about affordability, consolidation, and transparency become politically salient. The CMA said UK households spent more than £6.7 billion in the sector and noted that vet fees had risen faster than inflation, while many pet parents still lacked clear pricing or ownership information. That combination created a policy opening for direct intervention in areas that practices often view as operational or professional rather than antitrust issues. For US readers, the takeaway isn’t that the same rules are imminent, but that veterinary businesses are increasingly being judged not only on clinical outcomes, but also on pricing clarity, consent processes, complaints systems, and how corporate structures affect trust. (gov.uk)

What to watch: The implementation phase now matters as much as the headline reforms. The CMA’s public timetable shows draft funding orders and undertakings in spring 2026, draft substantive remedies orders in summer 2026, and a statutory deadline of September 23, 2026 for implementing remedial action, with most remedies expected to take effect within three to 12 months once orders are made and smaller businesses getting extra time. How smoothly those timelines hold, and how practices absorb the compliance burden, will determine whether the package becomes a model for future veterinary regulation or a cautionary tale about unintended consequences. (gov.uk)